 |
Prospector
Profile
07.1222
|
| |
| Inspire Pharmaceuticals, Inc. |
NAICS |
541710 |
| 4222 Emperor Boulevard, Suite 200
Durham, NC 27703 |
Description |
Biotechnology |
| (919) 941-9777 |
Employees |
170 |
| http://www.inspirepharm.com/ |
Revenue |
(mil) |
37.0598 |
| |
Income |
(mil) |
-42.1150 |
| |
Assets |
(mil) |
116.6990 |
| |
Liability |
(mil) |
38.3280 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Inspire Pharmaceuticals, Inc. reported a net loss of $5,877,000 for the three months ended June 30, 2007, compared to a net loss of $5,377,000 for the same period last year. For the first half of 2007, the Company reported a net loss of $31,992,000, compared to a net loss of $19,404,000 during the first half of 2006. The Company has an accumulated deficit of $277,117,000 as of June 30, 2007.
|
| |
|
Intellectual Property:
Patent applications have been filed on discoveries made in support of the WARF and Boehringer Ingelheim technologies, from research conducted with collaborators and in its own laboratories. The Company seeks patent protection for proprietary technology and products in the United States and Canada and in key commercial European and Asia/Pacific countries and other major commercial sectors of the world. It also relies upon trade secrets, know-how, continuing technological innovation and licensing opportunities to develop and maintain competitive position. On February 15, 2007, the Company entered into a license agreement with InSite Vision pursuant to which it licensed exclusive rights to commercialize AzaSite, as well as other potential topical anti-infective products containing azithromycin for use in the treatment of human ocular or ophthalmic indications. The Company also entered into an agreement with Allergan, Inc. to develop and commercialize the product candidates Prolacria™ and Restasis for the treatment of dry eye disease. In October 2006, the Company entered into a licensing agreement with FAES Farma SA for the U.S. and Canadian development and commercialization of bilastine. In November 2004, the Company licensed several patents for use in developing and commercializing new treatments for glaucoma from Wisconsin Alumni Research Foundation. [SEC Filing 10-K 03-16-07]
|
| |
|
Description:
The Company engages in the discovery, development, and commercialization of prescription pharmaceutical products.
|
| |
|
Officers:
Kenneth B. Lee, Jr. (Chair); Christy L. Shaffer (Pres., CEO & Dir.); Thomas R. Staab II (CFO & Treas.); Kip A. Frey (Dir.); Nancy J. Huston (Dir.); William R. Ringo, Jr. (Dir.); Richard S. Kent (Dir.)
|
| |
|
Auditor:
PricewaterhouseCoopers LLP
|
| |
|
Securities:
Common Stock-Symbol ISPH; NasdaqGM;
42,408,120 common shares outstanding as of June 30, 2007.
|
| |
| |
| |
| return to main page |
|
|
